Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.